Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies.

Publication: Lancet Diabetes Endocrinology

Jason H Y Wu, Matti Marklund,  Fumiaki Imamura, Nathan Tintle, Andres V Ardisson Korat, Janette de Goede,  Xia Zhou,  Wei-Sin Yang,  Marcia C de Oliveira Otto,  Janine Kröger, Waqas Qureshi,  Jyrki K Virtanen,  Julie K Bassett,  Alexis C Frazier-Wood,  Maria Lankinen,  Rachel A Murphy,  Kalina Rajaobelina,  Liana C Del Gobbo,  Nita G Forouhi,  Robert Luben,  Kay-Tee Khaw, Nick Wareham, Anya Kalsbeek, ,Jenna Veenstra, Juhua Luo,  Frank B Hu,  Hung-Ju Lin,  David S Siscovick,  Heiner Boeing,  Tzu-An Chen,  Brian Steffen,  Lyn M Steffen,  Allison Hodge,  Gudny Eriksdottir,  Albert V Smith,  Vilmunder Gudnason,  Tamara B Harris,  Ingeborg A Brouwer,  Claudine Berr,  Catherine Helmer,  Cecilia Samieri,  Markku Laakso,  Michael Y Tsai,  Graham G Giles,  Tarja Nurmi,  Lynne Wagenknecht, Matthias B Schulze, Rozenn N Lemaitre,  Kuo-Liong Chien,  Sabita S Soedamah-Muthu,  Johanna M Geleijnse,  Qi Sun,  William S Harris,  Lars Lind,  Johan Ärnlöv,  Ulf Riserus, Renata Micha,  Dariush Mozaffarian,  for theCohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE)

01 December 2017


Summary

The metabolic effects of omega-6 polyunsaturated fatty acids (PUFAs) remain contentious, and little evidence is available regarding their potential role in primary prevention of type 2 diabetes. We aimed to assess the associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes.

View publication

© Copyright - NIHR Cambridge Biomedical Research Centre 2025